BioSpace News Archive

Surgalign Spine Technologies, a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, announced it plans to release financial results from the first quarter 2022 after the close of trading on May 10th, 2022.

Treadwell Therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-400945, a first in class inhibitor of Polo-like kinase 4 (PLK4), for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML).

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022.

IntelGenx Technologies Corp. announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 3, 2022 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its acquisition of AltheaDx, Inc. (AltheaDx).

SCYNEXIS, Inc. announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), today announced that it has filed a clinical trial application with the Human Research Ethics Committee (HREC) in Australia in order to initiate the Phase I ATRIUM trial of ATG-018 in patients with advanced solid tumors and hematologic malignancies.

Aclarion, Inc. announced the closing of its previously announced initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock.

Zymo Research and Star Array announced Zymo Research’s strategic investment to acquire an interest in Star Array, a privately owned, biomedical technology company based in Singapore.